NCT06923397View on ClinicalTrials.gov

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
LymphomaLymphoma, HodgkinLymphoma, Non-HodgkinSedentary Behavior
Interventions
BEHAVIORAL

Interrupted Sedentary Time Intervention

A 12-week, semi-supervised exercise intervention comprised of reminder prompts, counseling, and activities of walking, cycling, and resistance band exercise for at-home and in-clinic settings. Supervision will be under an exercise trainer. Resistance bands, Libre Pro continuous blood sugar monitor, and Fitbit and ActivPAL trackers will be provided to participants.

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT06923397 - Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | Biotech Hunter | Biotech Hunter